SGLT2 Inhibitors Cut Risk for Adverse Outcomes in Acute Kidney Disease

Clinicians should consider incorporating sodium-glucose cotransport 2 inhibitors into the management of acute kidney disease and type 2 diabetes, according to investigators. Research confirms the benefits of using sodium-glucose cotransport 2 inhibitors (SGLT2is) in patients with acute kidney disease.

Related Keywords

Nuffield ,Oxfordshire ,United Kingdom ,National Taiwan University Hospital ,T Ai Pei ,Taiwan ,United States ,Taipei ,American ,Williamg Herrington , ,University Of Oxford Nuffield ,Journal Of The American Society Nephrology ,American Society ,Oxford Nuffield ,